**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claims 1-29 (canceled)

Claim 30 (previously presented) A pharmaceutical formulation comprising risperidone form B.

Claim 31 (previously presented) The pharmaceutical formulation of claim 30 wherein the risperidone form B is characterized by x-ray powder diffraction peaks at 14.0±0.2 and 21.7±0.2 degrees two-theta.

Claim 32 (previously presented) The pharmaceutical formulation of claim 30 wherein the risperidone form B is characterized by x-ray powder diffraction peaks at 10.8±0.2, 11.9±0.2, 12.6±0.2, 14.0±0.2, 17.5±0.2, 18.3±0.2, 19.9±0.2, 21.0±0.2, 21.7±0.2 degrees two-theta.

Claim 33 (previously presented) The pharmaceutical formulation of claim 30 wherein the risperidone form B is characterized by a x-ray powder diffraction pattern substantially depicted in Figure 2.

Claim 34 (previously presented) The pharmaceutical formulation of claim 30, 31, 32 or 33 wherein the pharmaceutical formulation is a dosage form suitable for oral administration or intravenous administration.

Claim 35 (previously presented) The pharmaceutical formulation of claim 34 wherein the dosage form is selected from the group consisting of tablet, coated pill,

dragee, sachet, hard capsule, gelatin capsule, sub-lingual table, syrup and suspension.

Claim 36 (previously presented) A method for treating a patient comprising the step of administering to the patient the pharmaceutical formulation of claim 30, 31, 32 or 33.

Claims 37 (previously presented) The method of claim 36, wherein the pharmaceutical formulation is administered at a daily dosage of about 4 to about 16 mg per day.

Claim 38 (previously presented) The method of claim 36, wherein the pharmaceutical formulation is administered at a daily dosage of about 4 to about 8 mg per day.

Claim 39 (previously presented) A pharmaceutical dosage formulation comprising an active ingredient and at least one component selected from the group consisting of pharmaceutical acceptable carrier and pharmaceutical acceptable excipient wherein the active ingredient consists essentially of risperidone form B.

Claim 40 (previously presented) The pharmaceutical dosage formulation of claim 39 wherein the dosage formulation is selected from the group consisting of tablet, coated pill, dragee, sachet, hard capsule, gelatin capsule, sub-lingual table, syrup and suspension.

Claim 41 (previously presented) A method of treating a patient comprising the step of administering to the patient the pharmaceutical dosage formulation of claim 39 or 40, wherein the pharmaceutical dosage formulation is administered at a daily dosage of about 4 to about 16 mg per day.